JP2018521086A - 硫酸デキストランの新しい使用 - Google Patents
硫酸デキストランの新しい使用 Download PDFInfo
- Publication number
- JP2018521086A JP2018521086A JP2018503496A JP2018503496A JP2018521086A JP 2018521086 A JP2018521086 A JP 2018521086A JP 2018503496 A JP2018503496 A JP 2018503496A JP 2018503496 A JP2018503496 A JP 2018503496A JP 2018521086 A JP2018521086 A JP 2018521086A
- Authority
- JP
- Japan
- Prior art keywords
- dextran sulfate
- acceptable salt
- pharmaceutically acceptable
- subject
- fibrosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229960000633 dextran sulfate Drugs 0.000 title claims abstract description 135
- 206010028594 Myocardial fibrosis Diseases 0.000 claims abstract description 29
- 238000007910 systemic administration Methods 0.000 claims abstract description 24
- 238000011282 treatment Methods 0.000 claims abstract description 17
- 230000005764 inhibitory process Effects 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims description 75
- 206010016654 Fibrosis Diseases 0.000 claims description 60
- 230000004761 fibrosis Effects 0.000 claims description 60
- 208000010125 myocardial infarction Diseases 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 18
- 210000002216 heart Anatomy 0.000 claims description 17
- 230000037396 body weight Effects 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 206010061216 Infarction Diseases 0.000 claims description 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 230000007574 infarction Effects 0.000 claims description 8
- 239000011593 sulfur Substances 0.000 claims description 8
- 229910052717 sulfur Inorganic materials 0.000 claims description 8
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 238000005481 NMR spectroscopy Methods 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- 230000001746 atrial effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229920002307 Dextran Polymers 0.000 claims description 2
- 229960002086 dextran Drugs 0.000 claims description 2
- 208000031225 myocardial ischemia Diseases 0.000 claims description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims 1
- 241001465754 Metazoa Species 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 11
- 210000000056 organ Anatomy 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 210000005003 heart tissue Anatomy 0.000 description 7
- 230000002939 deleterious effect Effects 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 210000002808 connective tissue Anatomy 0.000 description 5
- 230000003176 fibrotic effect Effects 0.000 description 5
- 230000000302 ischemic effect Effects 0.000 description 5
- 230000001575 pathological effect Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000001627 detrimental effect Effects 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003510 anti-fibrotic effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 239000007943 implant Substances 0.000 description 3
- 238000002513 implantation Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000001542 size-exclusion chromatography Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229920006318 anionic polymer Polymers 0.000 description 2
- 238000000149 argon plasma sintering Methods 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000007717 exclusion Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000009795 fibrotic process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000036573 scar formation Effects 0.000 description 2
- 230000037390 scarring Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 230000002861 ventricular Effects 0.000 description 2
- RQPKNXVVIBYOBX-KDBLBPRBSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-2-(dihydroxyamino)-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.ON(O)[C@H](C(O)=O)CC1=CC=CC=C1 RQPKNXVVIBYOBX-KDBLBPRBSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 108060003393 Granulin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010072877 Intestinal fibrosis Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004378 air conditioning Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000001130 astrocyte Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007331 pathological accumulation Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000009092 tissue dysfunction Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/721—Dextrans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/02—Dextran; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
【選択図】図1
Description
本研究では、心筋梗塞(MI)のラットモデルでの線維化の阻害または低減における硫酸デキストランの効果を評価した。
ラットにおける心筋梗塞モデルは、壁内縫合(intramural stitch)による永久的な左冠動脈の結紮を伴った。この手術は血流の閉塞を引き起こし、その後、重度の虚血性損傷および心臓壁の梗塞に至った。
マッソン・トリクローム染色で染色した心臓の切片において、梗塞の辺縁領域における間質線維化を手作業で評価した。間質線維化の面積を左心室の総面積のパーセントとして算出した。各ラットについて、5つの断面を分析した。梗塞の辺縁ゾーンにおける間質線維化の程度を図1に示す。
Claims (17)
- 対象における心筋線維化の処置、阻害または防止における使用のための前記対象への全身投与用に製剤化された、硫酸デキストランまたは医薬的に許容されるその塩。
- 心筋梗塞または心筋虚血に罹患したことがある前記対象における心筋線維化の処置、阻害または防止における使用のための前記対象への全身投与用に製剤化された、請求項1に記載の使用のための硫酸デキストランまたは医薬的に許容されるその塩。
- 前記硫酸デキストランまたは医薬的に許容されるその塩が、前記対象への静脈内投与または皮下投与のために製剤化される、請求項1または2に記載の使用のための硫酸デキストランまたは医薬的に許容されるその塩。
- 前記硫酸デキストランまたは医薬的に許容されるその塩が、10000Da以下の平均分子量を有する、請求項1〜3のいずれか1項に記載の使用のための硫酸デキストランまたは医薬的に許容されるその塩。
- 前記平均分子量が、2000〜10000Daの範囲内、好ましくは3000〜10000Daの範囲内、より好ましくは3500〜9500Daの範囲内、4500〜7500Daの範囲内など、および好ましくは4500〜5500Daの範囲内である、請求項4に記載の使用のための硫酸デキストランまたは医薬的に許容されるその塩。
- 前記硫酸デキストランまたは医薬的に許容されるその塩が、1850〜2000Daの範囲内の核磁気共鳴(NMR)分光法によって測定される数平均分子量(Mn)を有する、請求項4に記載の使用のための硫酸デキストランまたは医薬的に許容されるその塩。
- 前記硫酸デキストランまたは医薬的に許容されるその塩が、平均で5.1個のグルコース単位と2.6〜2.7のグルコース単位あたりの平均硫酸数とを有する、請求項6に記載の使用のための硫酸デキストランまたは医薬的に許容されるその塩。
- 前記硫酸デキストランまたは医薬的に許容されるその塩が、15〜20%の範囲で平均硫黄含有量を有する、請求項1〜7のいずれか1項に記載の使用のための硫酸デキストランまたは医薬的に許容されるその塩。
- 前記平均硫黄含有量が約17%である、請求項8に記載の使用のための硫酸デキストランまたは医薬的に許容されるその塩。
- 前記硫酸デキストランまたは医薬的に許容されるその塩が、注射用水溶液として製剤化される、請求項1〜9のいずれか1項に記載の使用のための硫酸デキストランまたは医薬的に許容されるその塩。
- 前記硫酸デキストランまたは医薬的に許容されるその塩が、連続した複数週間(連続した3週間など)にわたる1週間に複数回(3回など)の全身投与のために製剤化される、請求項1〜10のいずれか1項に記載の使用のための硫酸デキストランまたは医薬的に許容されるその塩。
- 前記硫酸デキストランまたは医薬的に許容されるその塩が、前記対象の体重の0.05〜50mg/kg、好ましくは前記対象の体重の0.05〜30mg/kg、およびより好ましくは前記対象の体重の0.1〜15mg/kgまたは0.1〜10mg/kgの範囲の投与量で投与されるように製剤化される、請求項1〜11のいずれか1項に記載の使用のための硫酸デキストランまたは医薬的に許容されるその塩。
- 前記対象が、心内膜心筋線維症、心筋梗塞の後の線維症または心房線維症からなる群より選択される疾患または障害に罹患している、請求項1〜12のいずれか1項に記載の使用のための硫酸デキストランまたは医薬的に許容されるその塩。
- 前記硫酸デキストランまたは医薬的に許容されるその塩が、前記対象の心臓の梗塞領域における間質線維化の処置、阻害または防止における使用のためのものである、請求項1〜13のいずれか1項に記載の使用のための硫酸デキストランまたは医薬的に許容されるその塩。
- 前記医薬的に許容されるその塩が、硫酸デキストランのナトリウム塩である、請求項1〜14のいずれか1項に記載の使用のための硫酸デキストランまたは医薬的に許容されるその塩。
- 対象における心筋線維化の処置、阻害または防止のための全身投与用に製剤化される医薬の製造のための硫酸デキストランまたは医薬的に許容されるその塩の使用。
- 対象において心筋線維化を処置、阻害または防止する方法であって、前記対象に、硫酸デキストランまたは医薬的に許容されるその誘導体を全身投与することを含む、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1551050A SE539575C2 (en) | 2015-07-30 | 2015-07-30 | Dextran sulfate for use in treating, inhibiting or preventing cardiac fibrosis |
SE1551050-6 | 2015-07-30 | ||
PCT/SE2016/050720 WO2017018922A1 (en) | 2015-07-30 | 2016-07-15 | New use of dextran sulfate |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018521086A true JP2018521086A (ja) | 2018-08-02 |
JP2018521086A5 JP2018521086A5 (ja) | 2018-09-13 |
JP6837679B2 JP6837679B2 (ja) | 2021-03-03 |
Family
ID=57884849
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018503496A Active JP6837679B2 (ja) | 2015-07-30 | 2016-07-15 | 硫酸デキストランの新しい使用 |
Country Status (11)
Country | Link |
---|---|
US (1) | US10478451B2 (ja) |
EP (1) | EP3328395B1 (ja) |
JP (1) | JP6837679B2 (ja) |
CN (2) | CN107921055A (ja) |
BR (1) | BR112018001942A2 (ja) |
DK (1) | DK3328395T3 (ja) |
EA (1) | EA034313B1 (ja) |
ES (1) | ES2882115T3 (ja) |
HK (1) | HK1246640A1 (ja) |
SE (1) | SE539575C2 (ja) |
WO (1) | WO2017018922A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021514881A (ja) * | 2018-03-09 | 2021-06-17 | カルメダ エービー | 生物学的実体の固定方法の改善 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL3532072T3 (pl) * | 2017-05-17 | 2020-09-21 | Tx Medic Ab | Leczenie jaskry |
WO2018212708A1 (en) * | 2017-05-17 | 2018-11-22 | Tx Medic Ab | Treatment of glaucoma |
EP3678675A4 (en) * | 2017-09-08 | 2021-07-07 | TX Medic AB | NEW USE OF DEXTRAN SULFATE |
SE543275C2 (en) * | 2019-03-07 | 2020-11-10 | Tx Medic Ab | Treatment efficiency evaluation |
SE544447C2 (en) * | 2020-09-29 | 2022-05-31 | Tx Medic Ab | Treatment of fatty liver diseases |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06508356A (ja) * | 1991-05-31 | 1994-09-22 | グリアテック,インコーポレーテッド | アニオン性ポリマーによる細胞侵入及び線維過多の抑制に基づく方法及び組成物 |
CN102973593A (zh) * | 2012-11-26 | 2013-03-20 | 合肥博太医药生物技术发展有限公司 | 硫酸葡聚糖在制备治疗肝纤维化药物中的应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0868191A1 (en) | 1995-12-18 | 1998-10-07 | Stichting Sanquin Bloedvoorziening | Potentiation of complement and coagulation inhibitory properties of c1-inhibitor. |
US20040224922A1 (en) | 1999-08-26 | 2004-11-11 | Malcolm King | Use of charged dextran as a mucoactive agent and methods and pharmaceutical compositions relating thereto |
SE525461C3 (sv) * | 2002-11-28 | 2005-03-23 | Prophymed Ab | Ny användning av dextransulfat |
WO2008134430A1 (en) * | 2007-04-24 | 2008-11-06 | Novelmed Therapeutics Inc. | Methods and compositions of inhibiting complement and cellular activation with dextran sulfate |
WO2015190989A1 (en) * | 2014-06-12 | 2015-12-17 | Tx Medic Ab | The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject |
-
2015
- 2015-07-30 SE SE1551050A patent/SE539575C2/en unknown
-
2016
- 2016-07-15 BR BR112018001942A patent/BR112018001942A2/pt not_active Application Discontinuation
- 2016-07-15 WO PCT/SE2016/050720 patent/WO2017018922A1/en active Application Filing
- 2016-07-15 DK DK16830923.5T patent/DK3328395T3/da active
- 2016-07-15 EA EA201890212A patent/EA034313B1/ru not_active IP Right Cessation
- 2016-07-15 ES ES16830923T patent/ES2882115T3/es active Active
- 2016-07-15 EP EP16830923.5A patent/EP3328395B1/en active Active
- 2016-07-15 US US15/748,519 patent/US10478451B2/en active Active
- 2016-07-15 CN CN201680044788.3A patent/CN107921055A/zh active Pending
- 2016-07-15 CN CN202210555037.5A patent/CN114712385A/zh active Pending
- 2016-07-15 JP JP2018503496A patent/JP6837679B2/ja active Active
-
2018
- 2018-05-09 HK HK18106000.5A patent/HK1246640A1/zh unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06508356A (ja) * | 1991-05-31 | 1994-09-22 | グリアテック,インコーポレーテッド | アニオン性ポリマーによる細胞侵入及び線維過多の抑制に基づく方法及び組成物 |
CN102973593A (zh) * | 2012-11-26 | 2013-03-20 | 合肥博太医药生物技术发展有限公司 | 硫酸葡聚糖在制备治疗肝纤维化药物中的应用 |
Non-Patent Citations (2)
Title |
---|
EUROPEAN HEART JOURNAL, vol. 26, JPN6020019903, 2005, pages 2334 - 2343, ISSN: 0004283885 * |
日本内科学会雑誌, vol. 103(9), JPN6020019905, 2014, pages 2188 - 2192, ISSN: 0004283886 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2021514881A (ja) * | 2018-03-09 | 2021-06-17 | カルメダ エービー | 生物学的実体の固定方法の改善 |
JP7365371B2 (ja) | 2018-03-09 | 2023-10-19 | カルメダ エービー | 生物学的実体の固定方法の改善 |
Also Published As
Publication number | Publication date |
---|---|
EP3328395A1 (en) | 2018-06-06 |
HK1246640A1 (zh) | 2018-09-14 |
ES2882115T3 (es) | 2021-12-01 |
WO2017018922A1 (en) | 2017-02-02 |
SE539575C2 (en) | 2017-10-17 |
BR112018001942A2 (pt) | 2018-09-18 |
CN107921055A (zh) | 2018-04-17 |
CN114712385A (zh) | 2022-07-08 |
EP3328395B1 (en) | 2021-06-09 |
EP3328395A4 (en) | 2018-06-20 |
US20180221403A1 (en) | 2018-08-09 |
DK3328395T3 (da) | 2021-08-09 |
SE1551050A1 (en) | 2017-01-31 |
EA201890212A1 (ru) | 2018-06-29 |
EA034313B1 (ru) | 2020-01-28 |
JP6837679B2 (ja) | 2021-03-03 |
US10478451B2 (en) | 2019-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6837679B2 (ja) | 硫酸デキストランの新しい使用 | |
JP2021152032A (ja) | トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療 | |
US10328098B2 (en) | Alginate biomaterials for the treatment of hepatic disorders | |
US10925890B2 (en) | Use of dextran sulfate | |
WO2015190989A1 (en) | The use of dextran sulfate having an average molecular weight below 10000 da for inducing angiogenisis in a subject | |
CN113613640A (zh) | 肾上腺素能β2受体激动剂R-对映体在治疗炎症性肠病及其肠外疾病的新应用 | |
JP2010521215A (ja) | 組織の修復を促進する方法 | |
US11186612B2 (en) | Substance P analog having progenitor cell or stem cell recruiting activity and method for progenitor cell or stem cell recruiting using the same | |
JP2022515615A (ja) | 慢性炎症性腸疾患の治療のためのpar-1アンタゴニストの使用 | |
EP3856249B1 (en) | Treatment of myocardial infarction | |
WO2020161158A1 (de) | Kardioprotektiver effekt des vasokonstriktion-inhibierenden faktors (vif) | |
JP2002538087A (ja) | 薬学的調製物を製造するためのオロソムコイドの使用 | |
SE538144C2 (sv) | Use of dextran sulfate for inducing angiogenesis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180711 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190610 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200520 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200616 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200911 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210105 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210127 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6837679 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |